Kleinostheim, Germany, 10th February 2011 - curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received FDA certification and, therefore, marketing authorization throughout the USA of the synthetic bone replacement material Osbone® Dental which already has been authorized in the EU as Osbone®.

Osbone® Dental is suitable for utilisation in general bone surgery, particularly in implantology and oral and maxillofacial surgery associated with jawbone atrophy.

The product consists of an open-celled, porous and biocompatible hydroxylapatite ceramic. It is extremely well tolerated by tissue, is not absorbable and is firmer than standard bone substance, which complies with the wishes of many physicians and dentists. Its spongy, interconnected cells match the natural bone trabecula structure, thereby allow integration into the surrounding viable bone. As a pure synthetic product Osbone® Dental has no biological origins, therefore, it is not associated with any risks relating to potential infections or the development of allergies.

Background information about curasan AG:

Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline, which will be ready for market rollout within the next few years via well-positioned contractual partners in various market segments.
www.curasan.com